Last reviewed · How we verify

NCT04543149

Immune Cells in Patients With Granulomatous Mastitis

Completed Last updated 12 January 2021
What this trial tests

trial testing Flow cytometric immunophenotyping in Granulomatous Mastitis in 35 participants. Completed in 10 October 2020.

Timeline
1 August 2020
Primary endpoint
1 October 2020
10 October 2020

Quick facts

Lead sponsorIstanbul Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment35
Start date1 August 2020
Primary completion1 October 2020
Estimated completion10 October 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Training and Research Hospital

Who can join

Adults 18 to 80, female only, with Granulomatous Mastitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying etiologies, including infectious and non-infectious causes. Etiological reasons were examined in various studies, but neither etiology nor definite criteria for diagnosis were found. Our aim in this study is to examine the role of immunophenotyping in differentiating the etiology of granulomatous mastitis and using it as a prognostic marker.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Flow cytometric immunophenotyping

Trials testing the same drug.

Other recruiting trials for Granulomatous Mastitis

Currently open trials in the same condition.

Other Istanbul Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04543149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing